research use only

Dextran sulfate sodium (DSS) HIV Protease inhibitor

Name: Dextran sulfate sodium (DSS)
Brand: Selleck Chemicals
SKU: S6929
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S6929

Dextran sulfate sodium (DSS) is a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro that inhibits virus adsorption to the host cells, and this compound can be used to induce animal models of Enteritis, Ulcerative Colitis.

Dextran sulfate sodium (DSS) HIV Protease inhibitor Chemical Structure

Molecular Weight: 36-50Kda

Jump to

Quality Control

Batch: Purity: 99%

Related Targets	HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease Tyrosinase DPP Serine Protease
Other HIV Protease Inhibitors	Pepstatin A Limonin Temsavir (BMS-626529) Bevirimat Rosamultin Mericitabine NBD-556 GS-6207 (Lenacapavir) Azvudine

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : 50 mg/mL
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.05mg/ml (0.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 1 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.05mg/ml (0.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 1 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	36-50Kda	Formula		Storage (From the date of receipt)	3 years -20°C powder
CAS No.	9011-18-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	HIV-1
References	[1] https://pubmed.ncbi.nlm.nih.gov/2457906/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-01)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date
NCT05710380	RECRUITING	Prostate Cancer; Prostate Adenocarcinoma; Prostate Neoplasm	University of Chicago	2023-04-26
NCT07246122	RECRUITING	Adolescent Idiopathic Scoliosis	Chinese University of Hong Kong	2023-07-27
NCT07063420	RECRUITING	Type 2 Diabetes Treated With Insulin	Daniel Chernavvsky, MD	2025-10-28
NCT06730282	UNKNOWN	Primary Dysmenorrhea (PD); Traditional Chinese Medicine (TCM) Approaches	Taichung Tzu Chi Hospital	2024-12-01
NCT04653961	UNKNOWN	Type1diabetes	Rabin Medical Center	2020-06-01
NCT07079787	NOT_YET_RECRUITING	Stroke; Mild Cognitive Impairment (MCI); Vestibular Disease; Long Covid-19	University College, London	2025-07-25

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):